8,700 Studies Reviewed. 87.0% Found Biological Effects. The Evidence is Clear.
Shield Your Body
Whole Body / General

Measurements for assessing the exposure from 3G femtocells

Bioeffects Seen

Boursianis A et al · 2011

Share:

Indoor femtocell deployment reduces user mobile phone transmission power without producing measurable increases in environmental electromagnetic field exposure at distances of approximately 1 meter.

Plain English Summary

Summary written for general audiences

This 2011 study measured electromagnetic field exposure from 3G femtocells (low-power indoor base stations) in Greek home and office environments. The measurements found that femtocell operation reduced mobile phone transmission power by at least 7 dB in 90% of measured locations, while producing negligible increases in electromagnetic field levels near the device compared to reference exposure guidelines.

Why This Matters

Femtocells represent a technology that can improve cellular coverage in indoor environments by reducing the distance between user devices and network access points. The study's finding that reduced handset transmission power occurs alongside minimal environmental field increases suggests a potential trade-off favorable to both user and environmental exposure metrics.

Exposure Information

Specific exposure levels were not quantified in this study.

Cite This Study
Boursianis A et al (2011). Measurements for assessing the exposure from 3G femtocells.
Show BibTeX
@article{measurements_for_assessing_the_exposure_from_3g_femtocells_ce1146,
  author = {Boursianis A et al},
  title = {Measurements for assessing the exposure from 3G femtocells},
  year = {2011},
  doi = {10.1089/apc.2011.0068},
  
}
DOI: 10.1089/apc.2011.0068PubMed: 22003184

Quick Questions About This Study

By 2009, 88% of HIV-exposed children had prenatal exposure to combination antiretroviral therapy (HAART), representing a dramatic increase from just 19% in 1997. Nearly 99% were exposed to at least one class of these medications.
Among children born in 2009, the most common exposures were zidovudine (73%), lamivudine (72%), tenofovir (39%), and emtricitabine (37%). Protease inhibitor exposure reached 86% by 2009, while NNRTI use declined significantly.
Higher maternal HIV RNA viral loads and lower CD4 counts were associated with increased likelihood of receiving combination antiretroviral therapy during pregnancy. Earlier timing of viral load measurements also correlated with treatment initiation.
The study analyzed data from 1,768 HIV-exposed children born between 1995 and 2009, providing a 14-year window into changing prenatal antiretroviral prescribing patterns as treatment guidelines evolved and new medications became available.
Since antiretroviral use during pregnancy continues to evolve and these medications can cross the placenta, researchers stress the need for ongoing monitoring to assess potential long-term developmental and health effects in exposed children.